MA54447A - Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer - Google Patents
Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimerInfo
- Publication number
- MA54447A MA54447A MA054447A MA54447A MA54447A MA 54447 A MA54447 A MA 54447A MA 054447 A MA054447 A MA 054447A MA 54447 A MA54447 A MA 54447A MA 54447 A MA54447 A MA 54447A
- Authority
- MA
- Morocco
- Prior art keywords
- octan
- azabicyclo
- pyrrolo
- triazol
- alzheimer
- Prior art date
Links
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212199 | 2018-12-13 | ||
| PCT/EP2019/084538 WO2020120521A1 (fr) | 2018-12-13 | 2019-12-11 | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer |
| EP19824250.5A EP3894411B1 (fr) | 2018-12-13 | 2019-12-11 | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés similaires en tant que modulateurs de la secretase gamma pour le traitement de la maladie d'alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54447A true MA54447A (fr) | 2022-03-23 |
| MA54447B1 MA54447B1 (fr) | 2024-08-30 |
Family
ID=64665266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54447A MA54447B1 (fr) | 2018-12-13 | 2019-12-11 | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés similaires en tant que modulateurs de la secretase gamma pour le traitement de la maladie d'alzheimer |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US12195470B2 (fr) |
| EP (2) | EP4424370A3 (fr) |
| JP (2) | JP7566745B2 (fr) |
| KR (1) | KR102910810B1 (fr) |
| CN (2) | CN117946116A (fr) |
| AR (1) | AR116906A1 (fr) |
| AU (1) | AU2019395774B2 (fr) |
| BR (1) | BR112021009443A2 (fr) |
| CA (1) | CA3117870A1 (fr) |
| CL (1) | CL2021001547A1 (fr) |
| CO (1) | CO2021006837A2 (fr) |
| CR (1) | CR20210305A (fr) |
| DK (1) | DK3894411T3 (fr) |
| ES (1) | ES2986688T3 (fr) |
| FI (1) | FI3894411T3 (fr) |
| HR (1) | HRP20241097T1 (fr) |
| HU (1) | HUE067669T2 (fr) |
| IL (2) | IL310081A (fr) |
| LT (1) | LT3894411T (fr) |
| MA (1) | MA54447B1 (fr) |
| MX (1) | MX2021006761A (fr) |
| MY (1) | MY208077A (fr) |
| PE (1) | PE20211776A1 (fr) |
| PH (1) | PH12021551387A1 (fr) |
| PL (1) | PL3894411T3 (fr) |
| PT (1) | PT3894411T (fr) |
| RS (1) | RS65821B1 (fr) |
| SG (1) | SG11202103340PA (fr) |
| SI (1) | SI3894411T1 (fr) |
| TW (1) | TWI831892B (fr) |
| UA (1) | UA129650C2 (fr) |
| WO (1) | WO2020120521A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3894411T1 (sl) * | 2018-12-13 | 2024-10-30 | F. Hoffmann - La Roche Ag | Derivati 7-fenoksi-N-(3-azabiciklo(3.2.1)oktan-8-il)-6,7-dihidro-5H- pirolo(1,2-b)(1,2,4)triazol-2-amina in sorodne spojine kot modulatorji gama-sekretaze za zdravljenje Alzheimerjeve bolezni |
| JP2022515610A (ja) | 2018-12-27 | 2022-02-21 | エフ．ホフマン－ラ ロシュ アーゲー | ｅｘｏ－ｔｅｒｔ－ブチルＮ－（３－アザビシクロ［３．２．１］オクタン－８－イル）カルバミン酸塩の調製のためのプロセス |
| KR20260027251A (ko) | 2023-06-19 | 2026-02-27 | 에프. 호프만-라 로슈 아게 | 카이랄 피롤로 트리아졸 알코올의 제조 공정 |
| WO2025228863A1 (fr) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Régime posologique pour un dérivé de 7-phénoxy-n- (3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5 h-pyrrolo[1,2-b][1,2,4]triazol-2-amine |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994349A (en) | 1997-10-27 | 1999-11-30 | Howard University | 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives |
| SK285908B6 (sk) | 1998-04-01 | 2007-10-04 | Nortran Pharmaceuticals Inc. | Aminocyklohexyléterová zlúčenina, kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny pri výrobe liečiva a pri liečbe |
| WO2000047547A2 (fr) | 1999-02-12 | 2000-08-17 | Nortran Pharmaceuticals Inc. | Composes d'amines cycloalkyles et utilisation de ceux-ci |
| US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
| US6448246B1 (en) | 1999-05-25 | 2002-09-10 | Neurogen Corporation | Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands |
| AU775102B2 (en) | 1999-09-13 | 2004-07-15 | David M. Swope | Composition and method for decreasing neurologic symptomatology |
| US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
| US7499263B2 (en) | 2005-08-30 | 2009-03-03 | Doosan Infracore Co., Ltd. | Mobile power source cable connection system and method |
| WO2007032009A2 (fr) | 2005-09-15 | 2007-03-22 | Biomas Ltd. | Utilisation de composes tellures pour le traitement du carcinome basocellulaire et/ou de la keratose actinique |
| DE602008004769D1 (en) | 2007-05-11 | 2011-03-10 | Hoffmann La Roche | Hetarylaniline als modulatoren für amyloid beta |
| AU2008312612B2 (en) | 2007-10-19 | 2013-11-28 | Janssen Pharmaceutica, N.V. | Piperidinyl and piperazinyl modulators of gamma-secretase |
| AU2009314049B2 (en) | 2008-11-13 | 2015-03-05 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| AU2010218714A1 (en) | 2009-02-26 | 2011-09-08 | Eisai R&D Management Co., Ltd. | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| WO2010138901A1 (fr) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés |
| CN102484127B (zh) | 2009-09-04 | 2015-07-15 | 惠普开发有限公司 | 基于混合金属价键化合物的记忆电阻 |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| EA023045B1 (ru) | 2011-07-15 | 2016-04-29 | Янссен Фармасьютикалз, Инк. | Новые замещенные производные индола в качестве модуляторов гамма-секретазы |
| US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
| CN107922437B (zh) | 2015-09-09 | 2021-12-10 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| EP3386978B1 (fr) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Dérivés de pipéridine pontés |
| EP3475279B1 (fr) | 2016-06-27 | 2021-07-14 | F. Hoffmann-La Roche AG | Triazolopyridines comme modulateurs de gamma-secretase |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| EP3535266B1 (fr) * | 2016-11-01 | 2021-12-29 | F. Hoffmann-La Roche AG | Dérivés hétéroaryle bicycliques |
| CN109790149B (zh) * | 2016-11-08 | 2022-05-17 | 豪夫迈·罗氏有限公司 | 苯氧基三唑类化合物 |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| WO2019141832A1 (fr) | 2018-01-22 | 2019-07-25 | F. Hoffmann-La Roche Ag | Dérivés de triazolo-azépine |
| SI3894411T1 (sl) * | 2018-12-13 | 2024-10-30 | F. Hoffmann - La Roche Ag | Derivati 7-fenoksi-N-(3-azabiciklo(3.2.1)oktan-8-il)-6,7-dihidro-5H- pirolo(1,2-b)(1,2,4)triazol-2-amina in sorodne spojine kot modulatorji gama-sekretaze za zdravljenje Alzheimerjeve bolezni |
-
2019
- 2019-12-11 SI SI201930802T patent/SI3894411T1/sl unknown
- 2019-12-11 CN CN202311792520.6A patent/CN117946116A/zh active Pending
- 2019-12-11 DK DK19824250.5T patent/DK3894411T3/da active
- 2019-12-11 RS RS20240883A patent/RS65821B1/sr unknown
- 2019-12-11 BR BR112021009443-1A patent/BR112021009443A2/pt unknown
- 2019-12-11 UA UAA202103248A patent/UA129650C2/uk unknown
- 2019-12-11 WO PCT/EP2019/084538 patent/WO2020120521A1/fr not_active Ceased
- 2019-12-11 EP EP24177200.3A patent/EP4424370A3/fr active Pending
- 2019-12-11 CN CN201980076253.8A patent/CN113179641B/zh active Active
- 2019-12-11 MY MYPI2021001956A patent/MY208077A/en unknown
- 2019-12-11 IL IL310081A patent/IL310081A/en unknown
- 2019-12-11 PH PH1/2021/551387A patent/PH12021551387A1/en unknown
- 2019-12-11 CR CR20210305A patent/CR20210305A/es unknown
- 2019-12-11 KR KR1020217017774A patent/KR102910810B1/ko active Active
- 2019-12-11 LT LTEPPCT/EP2019/084538T patent/LT3894411T/lt unknown
- 2019-12-11 MX MX2021006761A patent/MX2021006761A/es unknown
- 2019-12-11 PT PT198242505T patent/PT3894411T/pt unknown
- 2019-12-11 HU HUE19824250A patent/HUE067669T2/hu unknown
- 2019-12-11 MA MA54447A patent/MA54447B1/fr unknown
- 2019-12-11 ES ES19824250T patent/ES2986688T3/es active Active
- 2019-12-11 FI FIEP19824250.5T patent/FI3894411T3/fi active
- 2019-12-11 HR HRP20241097TT patent/HRP20241097T1/hr unknown
- 2019-12-11 AU AU2019395774A patent/AU2019395774B2/en active Active
- 2019-12-11 PL PL19824250.5T patent/PL3894411T3/pl unknown
- 2019-12-11 CA CA3117870A patent/CA3117870A1/fr active Pending
- 2019-12-11 IL IL283823A patent/IL283823B2/en unknown
- 2019-12-11 SG SG11202103340PA patent/SG11202103340PA/en unknown
- 2019-12-11 US US17/413,413 patent/US12195470B2/en active Active
- 2019-12-11 JP JP2021533563A patent/JP7566745B2/ja active Active
- 2019-12-11 PE PE2021000726A patent/PE20211776A1/es unknown
- 2019-12-11 EP EP19824250.5A patent/EP3894411B1/fr active Active
- 2019-12-12 AR ARP190103631A patent/AR116906A1/es unknown
- 2019-12-12 TW TW108145480A patent/TWI831892B/zh active
-
2021
- 2021-05-24 CO CONC2021/0006837A patent/CO2021006837A2/es unknown
- 2021-06-11 CL CL2021001547A patent/CL2021001547A1/es unknown
-
2024
- 2024-10-02 JP JP2024173048A patent/JP2025000919A/ja active Pending
- 2024-11-25 US US18/959,369 patent/US20250326758A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54447A (fr) | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| EP3528852A4 (fr) | Méthodes et compositions pour le traitement de la maladie de fabry | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| EP3541790C0 (fr) | Dérivés de 3-(2-(4-phénylpipérazin-1-yl)éthyl)-2-oxa-8-azaspiro[4.5]décan-1-one et composés similaires en tant que modulateurs du récepteur 7 de 5-hydroxytryptamine (5-ht7) pour le traitement de p.e. la maladie inflammatoire de l'intestin, trouble du rythme circadien ou dépression | |
| EP3953356C0 (fr) | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune | |
| MA49700A (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
| MA54132A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 | |
| MA51558A (fr) | Dérivés de 2,4,6,7-tétrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés apparentés en tant que modulateurs du récepteur c5a pour le traitement de la vascularite et de maladies inflammatoires | |
| EP3400942A4 (fr) | Utilisation de dérivés de quinoléine pour le traitement du cancer de l' sophage et procédé de traitement, composition pharmaceutique et trousse associée | |
| EP3496715A4 (fr) | Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques. | |
| MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| EP3529234A4 (fr) | Composés, procédé d'obtention des composés, composition pharmaceutique, utilisation des composés et procédé de traitement de troubles psychiatriques et/ou de troubles du sommeil | |
| EP3730144A4 (fr) | Agent pour le traitement d'une maladie du système nerveux | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| MX2019007103A (es) | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. | |
| EP3628008A4 (fr) | Compositions et méthodes pour le traitement de la maladie d'alzheimer | |
| EP2328877A4 (fr) | Composés de 1,4-benzoxazine, et dérivés de ceux-ci en tant que médicaments thérapeutiques pour le traitement de troubles neurodégénératifs | |
| EP3496716A4 (fr) | Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques. | |
| EP3463372A4 (fr) | Composés bicycliques fusionnés pour le traitement d'une maladie | |
| MA45665B1 (fr) | Dérivés d'éthynyle | |
| MA56186A (fr) | Composés pour le traitement d'une maladie respiratoire |